All In Biotech

Investigational drug · Phase 2

MDSY-1240

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic.

Phase 2

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "MDSY-1240"

First trial start

2026

Nov 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "MDSY-1240", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Triple-Negative Breast Cancer (TNBC)
  • Gastric Cancer (GC)
  • Gastric Cancer Adenocarcinoma Metastatic
  • Ovarian Cancer Metastatic
  • Ovarian Cancer Metastatic Recurrent
  • Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
  • Hepatocellular Carcinoma Metastatic
  • Classical Hodgkin Lymphoma Relapsed
  • Cutaneous T-Cell Lymphoma/Mycosis Fungoides
  • Cutaneous T-Cell Lymphoma/Sezary Syndrome

Approved drugs for the same conditions: Breast cancer · Ovarian cancer · Liver cancer (hepatocellular carcinoma) · Stomach and esophageal cancer · Head and neck cancer · Hodgkin lymphoma · Oncology · Hematology and blood cancers · Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "MDSY-1240" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Triple-Negative Breast Cancer (TNBC)

  • ESG401Phase 33 trials

    Qilu Pharmaceutical Co., Ltd. · Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC), Neoplasms, Breast

  • Dual-target CAR-NK cellsEB-DT-CAR-NK, Essen Biotech Dual-Target CAR-NKPhase 25 trials

    Beijing Biotech · HER2-positive Breast Cancer, Non-Small Cell Lung Cancer, Breast Cancer (Locally Advanced or Metastatic)

  • BreakVaxPhase 22 trials

    BreakBio Corp · Triple-Negative Breast Cancer (TNBC), Glioblastoma (GBM)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.